AGIO Insider Trading

Insider Ownership Percentage: 4.30%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $892,435.53

Agios Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at Agios Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$194ksoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$2M-$1M$0$1M$2MTotal Insider BuyingTotal Insider Selling

Agios Pharmaceuticals Share Price & Price History

Current Price: $28.74
Price Change: Price Decrease of -0.4 (-1.37%)
As of 05/13/2025 05:00 PM ET

This chart shows the closing price history over time for AGIO up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
JunJulAugSepOctNovDecJanFebMarAprMay$28.74Closing price on 05/13/25:

SEC Filings (Institutional Ownership Changes) for Agios Pharmaceuticals (NASDAQ:AGIO)

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at AGIO by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$18Mbought$9.50MsoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$100M$0$100MTotal InflowsTotal Outflows
Agios Pharmaceuticals logo
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Read More on Agios Pharmaceuticals

Today's Range

Now: $28.74
Low: $28.30
High: $29.59

50 Day Range

MA: $29.03
Low: $24.53
High: $32.71

52 Week Range

Now: $28.74
Low: $23.42
High: $62.58

Volume

511,844 shs

Average Volume

695,931 shs

Market Capitalization

$1.66 billion

P/E Ratio

2.53

Dividend Yield

N/A

Beta

0.77

Who are the company insiders with the largest holdings of Agios Pharmaceuticals?

Agios Pharmaceuticals' top insider shareholders include:
  1. Jacqualyn A Fouse (Director)
  2. Brian Goff (CEO)
  3. James William Burns (Insider)
  4. Sarah Gheuens (Insider)
  5. Cecilia Jones (CFO)
  6. Tsveta Milanova (Insider)
  7. David Scadden (Director)
  8. Kaye I Foster-Cheek (Director)
  9. Theodore James Jr Washburn (Insider)
Learn More about top insider investors at Agios Pharmaceuticals.

Who are the major institutional investors of Agios Pharmaceuticals?

Agios Pharmaceuticals' top institutional shareholders include:
  1. Vanguard Group Inc. — 9.68%
  2. Deutsche Bank AG — 1.60%
  3. GW&K Investment Management LLC — 1.41%
  4. Charles Schwab Investment Management Inc. — 0.80%
  5. Connor Clark & Lunn Investment Management Ltd. — 0.67%
  6. Bank of New York Mellon Corp — 0.46%
Learn More about top institutional investors of Agios Pharmaceuticals stock.

Which major investors are selling Agios Pharmaceuticals stock?

Within the previous quarter, AGIO stock was sold by these institutional investors:
  1. CenterBook Partners LP
  2. Vanguard Group Inc.
  3. Allianz Asset Management GmbH
  4. Headlands Technologies LLC
  5. GSA Capital Partners LLP
  6. Rhumbline Advisers
  7. Charles Schwab Investment Management Inc.
  8. Deutsche Bank AG
In the previous year, company insiders that have sold Agios Pharmaceuticals company stock include:
  1. Jacqualyn A Fouse (Director)
  2. Brian Goff (CEO)
  3. James William Burns (Insider)
  4. Sarah Gheuens (Insider)
  5. Cecilia Jones (CFO)
Learn More investors selling Agios Pharmaceuticals stock.

Which major investors are buying Agios Pharmaceuticals stock?

In the last quarter, AGIO stock was acquired by institutional investors including:
  1. Connor Clark & Lunn Investment Management Ltd.
  2. GW&K Investment Management LLC
  3. Universal Beteiligungs und Servicegesellschaft mbH
  4. Invesco Ltd.
  5. BIT Capital GmbH
  6. TD Asset Management Inc
  7. E Fund Management Co. Ltd.
  8. Commerce Bank